303 related articles for article (PubMed ID: 28087171)
1. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteremia treated with cefepime or ceftazidime.
Ratliff AR; Gentry CA; Williams RJ
Diagn Microbiol Infect Dis; 2017 Apr; 87(4):376-381. PubMed ID: 28087171
[TBL] [Abstract][Full Text] [Related]
2. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam.
Gentry CA; Williams RJ
Int J Antimicrob Agents; 2017 Mar; 49(3):333-338. PubMed ID: 28108367
[TBL] [Abstract][Full Text] [Related]
3. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.
Su TY; Ye JJ; Yang CC; Huang CT; Chia JH; Lee MH
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):52. PubMed ID: 28738848
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
McKinnon PS; Paladino JA; Schentag JJ
Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
6. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
7. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia.
Su TY; Ye JJ; Hsu PC; Wu HF; Chia JH; Lee MH
J Microbiol Immunol Infect; 2015 Apr; 48(2):175-82. PubMed ID: 24064286
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.
Crandon JL; Bulik CC; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2010 Mar; 54(3):1111-6. PubMed ID: 20038614
[TBL] [Abstract][Full Text] [Related]
10. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms.
Bhat SV; Peleg AY; Lodise TP; Shutt KA; Capitano B; Potoski BA; Paterson DL
Antimicrob Agents Chemother; 2007 Dec; 51(12):4390-5. PubMed ID: 17938179
[TBL] [Abstract][Full Text] [Related]
11. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
[TBL] [Abstract][Full Text] [Related]
12.
Pahlavanzadeh F; Kalantar-Neyestanaki D; Motamedifar M; Mansouri S
Yale J Biol Med; 2020 Mar; 93(1):29-34. PubMed ID: 32226332
[TBL] [Abstract][Full Text] [Related]
13. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?
Tamma PD; Turnbull AE; Milstone AM; Hsu AJ; Carroll KC; Cosgrove SE
Clin Infect Dis; 2012 Sep; 55(6):799-806. PubMed ID: 22696019
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of clinical outcomes in patients with Gram-negative bloodstream infections according to cefepime MIC.
Rhodes NJ; Liu J; McLaughlin MM; Qi C; Scheetz MH
Diagn Microbiol Infect Dis; 2015 Jun; 82(2):165-71. PubMed ID: 25801780
[TBL] [Abstract][Full Text] [Related]
15. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime.
Campo Esquisabel AB; Rodríguez MC; Campo-Sosa AO; Rodríguez C; Martínez-Martínez L
Clin Microbiol Infect; 2011 Dec; 17(12):1817-22. PubMed ID: 21599797
[TBL] [Abstract][Full Text] [Related]
17. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.
Lee NY; Lee CC; Li CW; Li MC; Chen PL; Chang CM; Ko WC
Antimicrob Agents Chemother; 2015 Dec; 59(12):7558-63. PubMed ID: 26416853
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).
Sader HS; Castanheira M; Farrell DJ; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2015 Dec; 83(4):389-94. PubMed ID: 26162518
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic therapy and clinical outcomes of Pseudomonas aeruginosa (PA) bacteraemia.
Tan SH; Teng CB; Ng TM; Lye DC
Ann Acad Med Singap; 2014 Nov; 43(11):526-34. PubMed ID: 25523856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
